Search Prime Grants

UH3DA050322

Cooperative Agreement

Overview

Grant Description
Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD.
Awardee
Place of Performance
Connecticut United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the total obligations have increased from $3,406,895 to $3,438,228.
Yale Univ was awarded Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD Cooperative Agreement UH3DA050322 worth $3,438,228 from National Institute on Drug Abuse in September 2019 with work to be completed primarily in Connecticut United States. The grant has a duration of 6 years and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Cooperative Agreement was awarded through grant opportunity Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional).

Status
(Complete)

Last Modified 6/20/23

Period of Performance
9/30/19
Start Date
9/29/25
End Date
100% Complete

Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UH3DA050322

Transaction History

Modifications to UH3DA050322

Additional Detail

Award ID FAIN
UH3DA050322
SAI Number
UH3DA050322-2456377782
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
FL6GV84CKN57
Awardee CAGE
4B992
Performance District
03
Senators
Richard Blumenthal
Christopher Murphy
Representative
Rosa DeLauro

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $3,438,228 100%
Modified: 6/20/23